Skip to main content
S&P 5007,670.84-0.17%DOW51,349.92-0.26%NASDAQ26,797.54-0.09%GOLD$4,213.90+0.82%OIL$88.58-0.90%
Delayed
Smart Investors Daily
GR

NASDAQ · GRCE

Grace Therapeutics, Inc.

Healthcare · Biotechnology

$2.12

Down-$0.01 (-0.47%)

Updated Sep 29, 2026, 10:26 PM

SID Score

3.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
47.49M
P/E ratio
-6.84
Dividend yield
0.00%
52-week range
$1.79 – $5.18
Volume
58.75K
Avg. volume
65.65K

Price performance · GRCE

GRCE price history

1M range · 0 trading sessions · Daily adjusted prices

GRCE does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest GRCE news

The latest Smart Investors Daily articles mentioning GRCE.

Stock researchCompany · Overview

Company

OverviewForecastEarnings — requires Earnings Calls and Results accessDividend — requires Dividend Research accessFinancials

Market Activity

OptionsInsider Trades — requires Insider Buying and Selling accessShort InterestInstitutional Ownership — requires Institutional Ownership accessSentiment

GRCE research

Overview

Company profile and research snapshot.

Company profile

Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage. Other products are GTx-102 Ataxia-Telangiectasia, GTx-101 Postherpetic Neuralgia, and GTx-201.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$11.90
Implied upside
—
Analysts
8
GRCE recent ratings
DateFirmRatingTarget
Apr 24, 2026TD CowenBuy—
Feb 18, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 3, 2026

Grace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment Conference

PRINCETON, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced that Chief Executive Officer Prashant Kohli will participate and present in the H.C. Wainwright 28th Annual Global Investment Conference, to be held

Benzinga · Aug 13, 2026

Grace Therapeutics Q1 EPS $(0.91) Misses $(0.18) Estimate

Grace Therapeutics (NASDAQ:GRCE) reported quarterly losses of $(0.91) per share which missed the analyst consensus estimate of $(0.18) by 405.56 percent. This is a 333.33 percent decrease over losses of $(0.21) per

Yahoo · Aug 5, 2026

Grace Therapeutics Announces $10 Million Private Placement

Expected gross proceeds anticipated to extend the Company’s cash runway to the end of calendar 2028PRINCETON, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (“Grace Therapeutics” or “the Company”), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced that it has entered into a securities purchase

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By